Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.

Magalhães Filho, Marcos Aurélio Fonseca; Aguiar, Pedro Nazareth; Neves, Milena Brachmans Mascarenhas; Lopes, Gilberto de Lima; Del Giglio, Auro

Magalhães Filho, Marcos Aurélio Fonseca; Aguiar, Pedro Nazareth; Neves, Milena Brachmans Mascarenhas; Lopes, Gilberto de Lima; Del Giglio, Auro.

Affiliation

Magalhães Filho MAF; Centro Universitário FMABC, Santo André, SP, Brazil.
Aguiar PN; Centro Universitário FMABC, Santo André, SP, Brazil.
Neves MBM; Centro Universitário FMABC, Santo André, SP, Brazil.
Lopes GL; Sylvester Comprehensive Cancer Center, Miami, FL, United States.
Del Giglio A; Centro Universitário FMABC, Santo André, SP, Brazil.

Einstein (Sao Paulo) ; 20: eGS6655, 2022.

Article in En | MEDLINE | ID: mdl-35544899

Subject(s)

Breast Neoplasms; Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/metabolism; Cost-Benefit Analysis; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2/metabolism; Receptor, ErbB-2/therapeutic use; Trastuzumab/therapeutic use; United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Health_economic_evaluation / Prognostic_studies Limits: Female / Humans Country/Region as subject: America do norte Language: En Journal: Einstein (Sao Paulo) Year: 2022 Document type: Article Affiliation country: Brazil

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google